BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Miwa H, Misawa H, Yamada T, Nagahara A, Ohtaka K, Sato N. Clarithromycin resistance, but not CYP2C-19 polymorphism, has a major impact on treatment success in 7-day treatment regimen for cure of H. pylori infection: a multiple logistic regression analysis. Dig Dis Sci. 2001;46:2445-2450. [PMID: 11713950 DOI: 10.1023/a:1012371702918] [Cited by in Crossref: 29] [Cited by in F6Publishing: 4] [Article Influence: 1.4] [Reference Citation Analysis]
Number Citing Articles
1 Tang HL, Li Y, Hu YF, Xie HG, Zhai SD. Effects of CYP2C19 loss-of-function variants on the eradication of H. pylori infection in patients treated with proton pump inhibitor-based triple therapy regimens: A meta-analysis of randomized clinical trials. PLoS One. 2013;8:e62162. [PMID: 23646118 DOI: 10.1371/journal.pone.0062162] [Cited by in Crossref: 58] [Cited by in F6Publishing: 47] [Article Influence: 6.4] [Reference Citation Analysis]
2 Sasaki M, Ogasawara N, Utsumi K, Kawamura N, Kamiya T, Kataoka H, Tanida S, Mizoshita T, Kasugai K, Joh T. Changes in 12-Year First-Line Eradication Rate of Helicobacter pylori Based on Triple Therapy with Proton Pump Inhibitor, Amoxicillin and Clarithromycin. J Clin Biochem Nutr. 2010;47:53-58. [PMID: 20664731 DOI: 10.3164/jcbn.10-10] [Cited by in Crossref: 62] [Cited by in F6Publishing: 57] [Article Influence: 5.2] [Reference Citation Analysis]
3 Isomoto H, Furusu H, Ohnita K, Wen CY, Inoue K, Kohno S. Sofalcone, a mucoprotective agent, increases the cure rate of Helicobacter pylori infection when combined with rabeprazole, amoxicillin and clarithromycin. World J Gastroenterol 2005; 11(11): 1629-1633 [PMID: 15786539 DOI: 10.3748/wjg.v11.i11.1629] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
4 Hojo M, Asaoka D, Takeda T, Shimada Y, Matsumoto K, Matsumoto K, Yatagai N, Akazawa Y, Ueda K, Ueyama H, Nagahara A. Randomized controlled study on the effects of triple therapy including vonoprazan or rabeprazole for the second-line treatment of Helicobacter pylori infection. Therap Adv Gastroenterol 2020;13:1756284820966247. [PMID: 33240391 DOI: 10.1177/1756284820966247] [Reference Citation Analysis]
5 Manes G, Pieramico O, Perri F, Vaira D, Giardullo N, Romano M, Nardone G, Balzano A. Twice-daily standard dose of omeprazole achieves the necessary level of acid inhibition for Helicobacter pylori eradication. A randomized controlled trial using standard and double doses of omeprazole in triple therapy. Dig Dis Sci. 2005;50:443-448. [PMID: 15810623 DOI: 10.1007/s10620-005-2455-6] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]